BeyondSpring secures Fast Track status and trades China subsidiary for trial funding
BeyondSpring ($BYSI) said the FDA granted Fast Track designation to plinabulin plus docetaxel for a defined previously treated non-squamous lung-cancer population. Separately, it signed an agreement to sell the holding company controlling its Chinese subsidiary to Biolin Investment. The consideration is noncash: Biolin’s obligations to support the China portion of the Phase III DUBLIN-4 trial and related development activities. China is expected to supply approximately 221 of the planned 442 pat
0